The Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) is adapting its organisational structure to help Europe’s industrial ecosystems recover more effectively from the COVID-crisis and to achieve the EU's digital and green goals.
On 30 October, the European Commission organised a multi-stakeholder conference in Brussels dedicated to biosimilar medicinal products. The meeting was organised in collaboration with the European Medicines Agency (EMA).
The European Commission and the European Medicines Agency (EMA)organised another multi-stakeholder event on biosimilar medicinal products to promote the exchange of knowledge and best practices in biosimilars' use and uptake.
The Commission is proposing a targeted adjustment to intellectual property rules to help Europe's pharmaceutical companies tap into fast-growing global markets and foster jobs, growth and investments in the EU.
Today, the European Commission published translations of comprehensive information for patients on biosimilar medicines.
The expert group is publishing a report. This report contains 9 guiding principles and 8 policy recommendations for jobs and growth through bio-based products.
Business Planet visits French bio-tech firm Transgene in Strasbourg to learn about immuno-oncology, where the DNA of specific viruses are modified so that they can track down cancer cells.
This guidance aims to help as many organisations as possible to obtain more information about bio-based products and to consider innovative bio-based products alongside other products when making their buying decisions.
More than 150 stakeholders shared their clinical experiences with and best practices in biological medicines including biosimilars on 5 May in Brussels.
The 2017 version of the report on biosimilar competition in Europe is now available.
This document has been developed to explain to patients in a clear, unbiased way what biosimilar medicines are, how they are developed and approved in the EU, and what patients can expect in terms of availability and safety.
The European Commission has published improved information for patients on biosimilar medicines. The Q&A were first published in 2013 and are available in all the 23 EU languages offering patients access to unbiased and reliable information.
Policy preparation at the European Commission is supported by both retrospective evaluations and forward-looking impact assessments.
This episode of Business Planet comes from the German city of Bonn. The team looks at a unique partnership between researchers, universities, pharmaceutical giants and small and medium-sized enterprises (SMEs) aimed at providing new treatments for patients and business opportunities for entrepreneurs.
The European Commission is seeking the views of European companies in the automotive, mechanical engineering and pharmaceutical sectors in order to tackle bottlenecks for digitalisation and to create an adequate environment to exploit its full potential.
More than 100 participants shared their experiences with biological medicines, including biosimilars, at national level. They discussed the information and communication needs of patients and healthcare professionals.
This report is an updated version of the IMS Health report 'The impact on biosimilar competition on price, volume and market share', first published in May 2015.
Counterfeit and pirated trade is a significant economic risk that undermines innovation and hampers economic growth. This open launch event will present the key findings of a joint OECD-EUIPO (EU International Patent Office) report that includes quantitative analysis on the value of trade in counterfeits and pirated goods worldwide.
This study presents key quantitative analysis on the exponential growth of trade in counterfeits and pirated goods worldwide. It highlights emerging trends, both globally and at country level, and the key industries affected by this illegal activity.
